GSK launches $2.5 billion savings drive to invest in drug pipeline

July 28 (Reuters) – GSK launched a £1.9 billion ($2.52 billion) cost-savings drive on Tuesday to help fund the British drugmaker's expanded late-stage study roster, aiming to deliver on CEO Luke Miels

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)